Business Context and Reporting Period
This Form 8-K filing by Avalo Therapeutics, Inc. (AVTX) is dated November 14, 2023. The report addresses the Company's status regarding its listing on the Nasdaq Capital Market following notices of non-compliance with minimum bid price and market value requirements.
Key Financial Metrics
The filing references specific financial data required to satisfy Nasdaq listing standards:
- Stockholders' Equity: $14.7 million (as reported in the Form 10-Q filed on November 9, 2023).
- Stock Price: The Company previously traded at $0.10 or less for ten consecutive trading days, triggering a potential delisting.
- Market Value of Listed Securities (MVLS): Previously below the $35 million minimum requirement.
The filing does not provide data on revenue, profit, cash flow, margins, or debt levels.
Material Changes and Listing Status
On November 14, 2023, the Nasdaq Hearings Panel granted the Company an exception to continue listing its securities until December 29, 2023. This decision followed a hearing on November 2, 2023, where the Company presented a plan to regain compliance. The Panel noted the Company had successfully demonstrated compliance with the stockholders' equity requirement ($2.5 million minimum) by filing its 10-Q.
Outlook, Conditions, and Risks
The continued listing is subject to strict conditions and carries significant risk:
- Compliance Deadline: The Company must maintain a closing bid price of $1.00 per share for ten consecutive trading sessions on or before December 29, 2023.
- Reporting Obligations: The Company must provide prompt notification of any significant events that may affect its ability to meet the exception terms.
- Delisting Risk: The Panel reserves the right to reconsider the exception if conditions change. The filing explicitly states there can be no assurance the Company will regain compliance with the Bid Price Rule.
Investor Verification Checklist
- Verify the current trading price of AVTX to assess progress toward the $1.00 per share requirement.
- Monitor the Company's ability to maintain the $1.00 bid price for ten consecutive days before the December 29, 2023 deadline.
- Review the Form 10-Q filed on November 9, 2023, for detailed financial position and liquidity status.
- Watch for any subsequent 8-K filings regarding significant events that could jeopardize the listing exception.